Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: Biochem Genet. 2009 Jun 30;47(0):688–693. doi: 10.1007/s10528-009-9266-y

Table 2. APOE genotypes and odds ratio of all-cause ESRD patients for the +APOE2 carriers vs. APOE3-3 homozygotes, stratified by time spend on haemodialysis treatment.

Time spend on
haemodialysis		 + APOE2 APOE3E3 +APOE4 Odds ratio (+E2 vs.
E3E3) (95% CI)
>8 years 60 (15.3%) 257 (65.5%) 75 (19.1%) 1.27 (0.94-1.71)
1-7 years 88 (16.3%) 340 (62.8%) 113 (20.9%) 1.41 (1.09-1.81)
1 year non-survivors 10 (22.2%) 28 (62.2%) 7 (15.6%) 1.94 (0.88-4.18)